 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/941924
Czech Republic Pharmaceuticals and Healthcare Report Q2 2009
|
Description: |
Czech Republic Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Czech Republic's pharmaceuticals and healthcare industry.
BMI forecasts that the Czech drug market will grow at a compound annual growth rate (CAGR) of 4.8% over the 2008-2013 period. Although this represents a fall on the 8.1% growth and 13.9% growth witnessed in 2008 and 2007 respectively, it is indeed encouraging in light of the economic turmoil in which many Eastern European countries now find themselves. In addition, growth levels at the end of 2007 were distorted by patients stockpiling medicines ahead of the introduction of co-payments at the beginning of 2008. While future healthcare reforms remain a key risk to our forecast scenario, an overall demand for more effective and modern treatments should continue to cause increased sales and prices. However, we believe the days of double-digit growth are over, in light of the Czech markets maturing status and increasingly negative pricing and reimbursement environment.
The biggest development of the quarter has seen French pharmaceutical Sanofi-Aventis receiving European Commission (EC) approval for its US$2.3bn acquisition of Czech generics firm Zentiva. EU antitrust regulators have ordered Sanofi-Aventis to divest 15 drugs in various countries due to their concerns over the level of risk associated with the deal. Regulators were particularly concerned that the deal could mean reduced choice and higher prices for hospitals, patients and governments in Central and Eastern Europe,. Sanofi has stressed that the sales will have only a limited impact on revenues, as the divested products collectively generated annual sales of approximately EUR18.0mn (US$23mn) in 2007.
Meanwhile, in January 2009, The Czech State Institute for Drug Control (SUKL) introduced a new system for prescribing medicines, allowing patients to obtain repeat prescriptions without needing to see a doctor. The system, which will allow doctors to send prescriptions via mobile phone using SMS, or email, means that patients will need only to be informed of the prescription's short identification code, following from which a patient will be able to collect their medicine from the pharmacy. Retailers are currently awaiting installation of connection with SUKL servers, which will allow them to verify prescriptions. Completion for most outlets is expected by the end of March 2009.
The Czech Republic has fallen to third place in Business Environment Rankings for the Central & Eastern European region. However, this has been largely due to faster improvement in scores for its regional neighbours, Greece and Slovakia. The Czech Republic is still let down by its sub-standard patent regime, which could harm the development of its biotech sector. |
|
Contents: |
Executive Summary
Czech Republic Pharmaceuticals And Healthcare Industry SWOT
Czech Republic Political SWOT
Czech Republic Economic SWOT
Czech Republic Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Czech Republic Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Intellectual Property Environment
Pricing And Reimbursement Issues
Healthcare Sector
Hospital Sector
Opposition to Health Fees
Industry Forecast Scenario
Overall Market Forecast
Table: Czech Republic’s Drug Market Forecast Indicators, 2004-2013
Key Growth Factors – Industry
Table: Czech Republic’s Health Expenditure Indicators, 2004-2013
Key Growth Factors – Macroeconomic
Table: Czech Republic – Economic Activity
Prescription Market Forecast
Table: Czech Republic – Prescription Market Indicators, 2004-2013 (US$mn unless otherwise indicated)
Patented Drug Market Forecast
Table: Patented Drugs Market Indicators, 2004-2013
Generics Market Forecasts
Table: Czech Republic’s Generics Market Forecast 2004-2013
OTC Market Forecast
Table: OTC Drugs Market Indicators, 2004-2012 (US$mn unless otherwise stated)
Medical Device Forecast
Czech Republic Medical Device Market Forecast
Export/Import Forecasts
Table: Czech Republic’s Pharmaceutical Trade Indicators, 2004-2013 (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Indicators
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Recent Company Developments
Research And Development Sector
Wholesale
Retail Sector
Company Monitor
Multinational Companies
AstraZeneca
Bristol-Myers Squibb
Sanofi-Aventis
Local Companies
Walmark
Zentiva (incorporating Sicomed)
Country Snapshot: Czech Republic Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources |
|
Companies Mentioned |
- AstraZeneca
- Bristol-Myers Squibb
- Sanofi-Aventis
- Walmark
- Zentiva (incorporating Sicomed) |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/941924
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 26/11/2009 01:09:22 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Czech Republic Pharmaceuticals and Healthcare Report Q2 2009
|
|
Web Address: |
http://www.researchandmarkets.com/reports/941924
|
|
Office Code: |
|
OC8HJNMPMSTQQ
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Single User
|
|
€440.00
|
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 26/11/2009 01:09:22
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
